Article

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.

2022-02-23

Abstract excerpt

<h4>Background: </h4> Biallelic inactivation of TP53 has been included in the definition of double-hit (DH) multiple myeloma (MM), which entails an ominous prognosis even when treated with the most innovative drugs. However, this condition, or even the presence of high-risk cytogenetic abnormalities, cannot accurately capture the 15-20% of the MM population with a median overall survival below 24 months. This prom...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f83507da-a254-56d1-b1a9-61b7c3795ed9
DOI: 10.21203/rs.3.rs-1380448/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.DOI 10.21203/rs.3.rs-1380448/v1Read

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisSemantic proximity Read

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.Semantic proximity Read

Genomic characterization of functional high-risk multiple myeloma patients.Semantic proximity Read

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaSemantic proximity Read

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.Semantic proximity Read

Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaSemantic proximity Read